Next Article in Journal
Work Ability in Patients with Chronic Myeloid Leukemia: A Danish Nationwide Cohort Study
Previous Article in Journal
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
Previous Article in Special Issue
Unlocking Glioblastoma Secrets: Natural Killer Cell Therapy against Cancer Stem Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 9
10.3390/cancers17091583
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2023, 15(20), 5038.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038

by
Laurent Turchi
1,2,
Nathalie Sakakini
1,
Gaelle Saviane
1,
Béatrice Polo
1,
Mirca Saras Saurty-Seerunghen
3,
Mathieu Gabut
4,5,
Corine Auge Gouillou
6,
Vincent Guerlais
7,
Claude Pasquier
7,
Marie Luce Vignais
8,
Fabien Almairac
1,9,
Hervé Chneiweiss
3,
Marie-Pierre Junier
3,
Fanny Burel-Vandenbos
1,10 and
Thierry Virolle
1,*
1
CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France
2
DRCI, CHU de Nice, 06107 Nice, France
3
CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Sorbonne Université, 75252 Paris, France
4
Stemness in Gliomas Laboratory, Cancer Initiation and Tumoral Cell Identity (CITI) Department, INSERM 1052, CNRS 5286, Centre Léon Bérard, 69008 Lyon, France
5
Cancer Research Center of Lyon 1, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France
6
UMR 1253, iBrain, Inserm, Université de Tours, 37000 Tours, France
7
CNRS, I3S, Université Côte d’Azur, 06560 Valbonne, France
8
CNRS, INSERM, Institut de Génomique Fonctionnelle, IGF, Université de Montpellier, 34090 Montpellier, France
9
Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, 06107 Nice, France
10
Service d’Anatomopathologie, Hôpital Pasteur, CHU de Nice, 06107 Nice, France
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(9), 1583; https://doi.org/10.3390/cancers17091583
Submission received: 14 March 2025 / Accepted: 7 April 2025 / Published: 7 May 2025
(This article belongs to the Special Issue Brain Cancer Stem Cells in Children and Adults)
Browse Figure
Versions Notes
In the original publication [1], errors were made in Figure 2. Panels 2A,C,E are incorrect and do not correspond to the original blot. The correct panels, in Figure 2, and caption are shown below. The authors apologize for any inconvenience caused and state that the scientific conclusions are not affected. This correction has been approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Turchi, L.; Sakakini, N.; Saviane, G.; Polo, B.; Saurty-Seerunghen, M.S.; Gabut, M.; Gouillou, C.A.; Guerlais, V.; Pasquier, C.; Vignais, M.L.; et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 01583 g002
Figure 2. CELF2 expression and regulation in patient-derived GSCs. (A) Western blot analysis showing CELF2 expression in proliferating GSCs and their serum-differentiated counterparts (three days of differentiation). (B) Western blot showing CELF2 expression during the time course of GSC differentiation in serum medium. (C) GB5, TG6 and GB1 have been transfected by a synthetic miR-199a-3p or by a control non-relevant miRNA. CELF2 expression is revealed in both condition by western blot. (D) Immunofluorescence showing the expression of CELF2 or Nestin (marker of GSCs) in GB5 stably expressing a synthetic miR-199a-3p or a control non-relevant sequence. Scale = 100 µM. Histogram on the right displays the quantification of the number of positive cells (p value < 0.0001 ****). (E) GB5, TG6 and GB1 have been transfected by an anti-miR-199a-3p (synthetic sequence) or by a non-relevant sequence as anti-miRNA control. CELF2 expression is revealed by western blot.
Figure 2. CELF2 expression and regulation in patient-derived GSCs. (A) Western blot analysis showing CELF2 expression in proliferating GSCs and their serum-differentiated counterparts (three days of differentiation). (B) Western blot showing CELF2 expression during the time course of GSC differentiation in serum medium. (C) GB5, TG6 and GB1 have been transfected by a synthetic miR-199a-3p or by a control non-relevant miRNA. CELF2 expression is revealed in both condition by western blot. (D) Immunofluorescence showing the expression of CELF2 or Nestin (marker of GSCs) in GB5 stably expressing a synthetic miR-199a-3p or a control non-relevant sequence. Scale = 100 µM. Histogram on the right displays the quantification of the number of positive cells (p value < 0.0001 ****). (E) GB5, TG6 and GB1 have been transfected by an anti-miR-199a-3p (synthetic sequence) or by a non-relevant sequence as anti-miRNA control. CELF2 expression is revealed by western blot.
Cancers 17 01583 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Turchi, L.; Sakakini, N.; Saviane, G.; Polo, B.; Saurty-Seerunghen, M.S.; Gabut, M.; Gouillou, C.A.; Guerlais, V.; Pasquier, C.; Vignais, M.L.; et al. Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038. Cancers 2025, 17, 1583. https://doi.org/10.3390/cancers17091583

AMA Style

Turchi L, Sakakini N, Saviane G, Polo B, Saurty-Seerunghen MS, Gabut M, Gouillou CA, Guerlais V, Pasquier C, Vignais ML, et al. Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038. Cancers. 2025; 17(9):1583. https://doi.org/10.3390/cancers17091583

Chicago/Turabian Style

Turchi, Laurent, Nathalie Sakakini, Gaelle Saviane, Béatrice Polo, Mirca Saras Saurty-Seerunghen, Mathieu Gabut, Corine Auge Gouillou, Vincent Guerlais, Claude Pasquier, Marie Luce Vignais, and et al. 2025. "Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038" Cancers 17, no. 9: 1583. https://doi.org/10.3390/cancers17091583

APA Style

Turchi, L., Sakakini, N., Saviane, G., Polo, B., Saurty-Seerunghen, M. S., Gabut, M., Gouillou, C. A., Guerlais, V., Pasquier, C., Vignais, M. L., Almairac, F., Chneiweiss, H., Junier, M.-P., Burel-Vandenbos, F., & Virolle, T. (2025). Correction: Turchi et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers 2023, 15, 5038. Cancers, 17(9), 1583. https://doi.org/10.3390/cancers17091583

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop